Ark Invest Goes Against the Grain: Wood Bets on Nvidia and the Gene-Editing Arena

Life Science

Eli Lilly Is on an M&A Spree—Will the $2.88 Billion Merida Deal Be Enough to Diversify?

Life Science

Viking Therapeutics Is Down 66% — Here’s What Could Bring It Back

Life Science

How to Choose Between Two Major Pharmaceutical Themed ETFs?

Financial Service, Life Science

Rasonque’s Lightning Approval Validates Druckenmiller’s Bet on Revolution Medicines

Life Science

Clinical-Stage Biotechnology Company Biohaven Sees Dual Positive Developments During the Week

Life Science

J&J’s 64-Year Dividend Streak Reinforces ‘Sleep-Well’ Stock Status

Life Science

Novo Nordisk’s Weight-Loss Oral Drug Makes New Progress in China Approval

Life Science

Billionaire Loads Up on Revolution Medicines, the Upside Could Be More Than 7%

Life Science

Beyond Eli Lilly and Novo Nordisk: Overlooked Opportunities in the GLP-1 Race

Life Science

mRNA Cancer Vaccine Trial Succeeds, Biotech Sector Sees Catalyst

Life Science

Shattuck Labs Jumps as Two Analysts Start Bullish Coverage

Life Science

Medicare Part D Subsidy Expires Next Year, Retirees Should Watch for Premium Changes

Life Science

Pharmacy Drag and Consumer Weakness Slow Wal-Mart’s Growth, with E-Commerce and Membership Businesses Becoming Future Highlights

Consumer Goods, Life Science

Cannabis Consolidation Wave Accelerates, ETF Allocation Value Stands Out

Cannabis